Your browser doesn't support javascript.
loading
Transportation of cellular therapy products: report of a survey by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) collaborative.
Pamphilon, D H; Selogie, E; Szczepiorkowski, Z M.
Afiliação
  • Pamphilon DH; NHS Blood and Transplant, North Bristol Park, Northway, Filton, Bristol, UK. derwood.pamphilon@nhsbt.nhs.uk
Vox Sang ; 99(2): 168-73, 2010 Aug 01.
Article em En | MEDLINE | ID: mdl-20230598
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Most cell therapy products (CTP) are infused or processed shortly after collection but in some cases this may be delayed for up to 48 h. A number of variables such as temperature and cell concentration are of critical importance for the integrity of CTP during this time. MATERIALS AND

METHODS:

We conducted a survey of cellular therapy laboratories to ascertain current practices for CTP transportation.

RESULTS:

There were 194 respondents of whom 90% shipped or received CTP--84% allogeneic, 71% autologous and 62% therapeutic cells. Processing facilities shipped or received the following products--hematopoietic progenitor cells (HPC), Marrow 73%; HPC, Apheresis 90%; HPC, Cord Blood 54% and others 14%. Other CTP included donor lymphocytes, mesenchymal stem cells (MSC), natural killer cells, buffy coat neutrophils and virus-specific cytotoxic T lymphocytes (CTL). More than 70% of respondents believed that it was acceptable for CTP to be held for up to 2 h without checking the temperature or cell density and a similar proportion agreed that putting products in containers to control parameters such as temperature within this time period was unnecessary. The majority of centres shipped or received between 1 and 10 CTP annually and 66% received products taking more than 2 h to ship. Of these, 82% specified the conditions for temperature in transit whilst 57% monitored temperature in transit and 74% of these used a data logger. The temperature range most commonly specified was 18-24 degrees C. The majority of processing facilities did not request an adjustment to the cell density even for products taking more than 2 h to reach their facility. More than 90% of respondents tested HPC for CD34(+) cells, viability and sterility; 40-48% performed colony-forming unit-granulocyte macrophage (CFU-GM) analysis. Only viability was thought by > 50% of respondents to be impacted by temperature, cell density and other parameters.

CONCLUSION:

Understanding current practice will help in the design of future studies for CTP storage and transportation.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia Biológica Limite: Humans Idioma: En Ano de publicação: 2010 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia Biológica Limite: Humans Idioma: En Ano de publicação: 2010 Tipo de documento: Article